Theravance Biopharma, Inc.
For the period ended Dec 31, 2025. Filed Mar 23, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 23, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits and Financial Statement Schedules
| 1. | Financial Statements: |
The following financial statements and schedules of the Registrant have been appended to this Annual Report on Form 10-K:
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 42) | | F-2 |
|---|---|---|
| Consolidated Balance Sheets as of December 31, 2025 and 2024 | | F-4 |
| Consolidated Statements of Operations for each of the two years in the period ended December 31, 2025 | | F-5 |
| Consolidated Statements of Comprehensive Income (Loss) for each of the two years in the period ended December 31, 2025 | | F-6 |
| Consolidated Statements of Shareholders’ Equity for each of the two years in the period ended December 31, 2025 | | F-7 |
| Consolidated Statements of Cash Flows for each of the two years in the period ended December 31, 2025 | | F-8 |
| Notes to Consolidated Financial Statements | | F-9 |
| Supplementary Financial Data (unaudited) | | F-39 |
| 2. | Financial Statement Schedules: |
All schedules have been omitted because of the absence of conditions under which they are required or because the required information, where material, is shown in the financial statements, financial notes or supplementary financial information.
| (b) | Exhibits required by Item 601 of Regulation S-K |
|---|
The information required by this Item is set forth on the exhibit index that precedes the signature page of this report.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.